Literature DB >> 16554120

Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.

Ronald L Klein1, Robert D Dayton, Karen M Henderson, Leonard Petrucelli.   

Abstract

Parkin is a ubiquitin ligase involved in the ubiquitin-proteasome system. Elevating parkin expression in cells reduces markers of oxidative stress while blocking parkin expression increases oxidative stress. In parkin gene knock down mouse and fly models, mitochondria function is deficient. Parkin is neuroprotective against a variety of toxic insults, while it remains unclear which of the above properties of parkin may mediate the protective actions. One of the models for which parkin is protective is overexpression of alpha-synuclein, a protein that self-aggregates in Parkinson disease. The microtubule-associated protein tau is another protein that self-aggregates in specific neurodegenerative diseases that also involve loss of dopamine neurons such as frontotemporal dementia with parkinsonism linked to chromosome 17, progressive supranuclear palsy and corticobasal degeneration. We recently developed a tau-induced dopaminergic degeneration model in rats using adeno-associated virus vectors. In this study, we successfully targeted either a mixed tau/parkin vector or mixed tau/control vector to the rat substantia nigra. While there was significant loss of dopamine neurons in the tau/control group relative to uninjected substantia nigra, there was no cell loss in the tau/parkin group. We found no difference in total tau levels between tau/control and tau/parkin groups. Parkin therefore protects dopamine neurons against tau as it does against alpha-synuclein, which further supports parkin as a therapeutic target for diseases involving loss of dopamine neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554120      PMCID: PMC2975302          DOI: 10.1016/j.neulet.2006.03.001

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  28 in total

1.  Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death.

Authors:  Frédéric Darios; Olga Corti; Christoph B Lücking; Cornelia Hampe; Marie-Paule Muriel; Nacer Abbas; Wen-Jie Gu; Etienne C Hirsch; Thomas Rooney; Merle Ruberg; Alexis Brice
Journal:  Hum Mol Genet       Date:  2003-03-01       Impact factor: 6.150

2.  Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.

Authors:  Leonard Petrucelli; Casey O'Farrell; Paul J Lockhart; Melisa Baptista; Kathryn Kehoe; Liselot Vink; Peter Choi; Benjamin Wolozin; Matthew Farrer; John Hardy; Mark R Cookson
Journal:  Neuron       Date:  2002-12-19       Impact factor: 17.173

3.  Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins.

Authors:  Ronald L Klein; Robert D Dayton; Nancy J Leidenheimer; Karen Jansen; Todd E Golde; Richard M Zweig
Journal:  Mol Ther       Date:  2005-12-01       Impact factor: 11.454

4.  Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.

Authors:  H Shimura; M G Schlossmacher; N Hattori; M P Frosch; A Trockenbacher; R Schneider; Y Mizuno; K S Kosik; D J Selkoe
Journal:  Science       Date:  2001-06-28       Impact factor: 47.728

5.  Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.

Authors:  John F Staropoli; Caroline McDermott; Cécile Martinat; Brenda Schulman; Elena Demireva; Asa Abeliovich
Journal:  Neuron       Date:  2003-03-06       Impact factor: 17.173

6.  Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome.

Authors:  Dong-Hoon Hyun; MoonHee Lee; Nobutaka Hattori; Shin-Ichiro Kubo; Yoshikuni Mizuno; Barry Halliwell; Peter Jenner
Journal:  J Biol Chem       Date:  2002-05-28       Impact factor: 5.157

7.  Improved detection of substantia nigra pathology in Alzheimer's disease.

Authors:  Julie A Schneider; Julia L Bienias; David W Gilley; David E Kvarnberg; Elliott J Mufson; David A Bennett
Journal:  J Histochem Cytochem       Date:  2002-01       Impact factor: 2.479

Review 8.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

Authors:  L Buée; T Bussière; V Buée-Scherrer; A Delacourte; P R Hof
Journal:  Brain Res Brain Res Rev       Date:  2000-08

9.  An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.

Authors:  Parvoneh Poorkaj; Nancy A Muma; Victoria Zhukareva; Elizabeth J Cochran; Kathleen M Shannon; Howard Hurtig; William C Koller; Thomas D Bird; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg
Journal:  Ann Neurol       Date:  2002-10       Impact factor: 10.422

10.  Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy.

Authors:  E Di Maria; M Tabaton; T Vigo; G Abbruzzese; E Bellone; C Donati; E Frasson; R Marchese; P Montagna; D G Munoz; P P Pramstaller; G Zanusso; F Ajmar; P Mandich
Journal:  Ann Neurol       Date:  2000-03       Impact factor: 10.422

View more
  12 in total

1.  Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Alexander M Herman; G William Rebeck; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2011-09-14       Impact factor: 4.314

Review 2.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

Review 3.  Inflammation in the early stages of neurodegenerative pathology.

Authors:  Preeti J Khandelwal; Alexander M Herman; Charbel E-H Moussa
Journal:  J Neuroimmunol       Date:  2011-08-05       Impact factor: 3.478

Review 4.  Twenty years since the discovery of the parkin gene.

Authors:  Nobutaka Hattori; Yoshikuni Mizuno
Journal:  J Neural Transm (Vienna)       Date:  2017-06-15       Impact factor: 3.575

5.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

Review 6.  The multiple mechanisms of amyloid deposition: the role of parkin.

Authors:  Maria A Mena; José A Rodríguez-Navarro; Justo García de Yébenes
Journal:  Prion       Date:  2009-01-09       Impact factor: 3.931

7.  Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity.

Authors:  Bin Liu; Roberta Traini; Bryan Killinger; Bernard Schneider; Anna Moszczynska
Journal:  Exp Neurol       Date:  2013-01-09       Impact factor: 5.330

8.  Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression.

Authors:  Jason B Tatom; David B Wang; Robert D Dayton; Omar Skalli; Michael L Hutton; Dennis W Dickson; Ronald L Klein
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

9.  The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases.

Authors:  Preeti J Khandelwal; Charbel E-H Moussa
Journal:  Front Psychiatry       Date:  2010-06-03       Impact factor: 4.157

Review 10.  Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology.

Authors:  Shaobin Yu; Ling Zhu; Qiang Shen; Xue Bai; Xuhui Di
Journal:  Behav Neurol       Date:  2015-03-12       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.